These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21482537)

  • 1. The window of opportunity in ACPA-positive rheumatoid arthritis is not explained by ACPA characteristics.
    Willemze A; van der Linden MP; le Cessie S; Trouw LA; Toes RE; Huizinga TW; van der Helm-van Mil AH
    Ann Rheum Dis; 2011 Sep; 70(9):1697-8. PubMed ID: 21482537
    [No Abstract]   [Full Text] [Related]  

  • 2. The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia.
    van de Stadt LA; van der Horst AR; de Koning MH; Bos WH; Wolbink GJ; van de Stadt RJ; Pruijn GJ; Dijkmans BA; van Schaardenburg D; Hamann D
    Ann Rheum Dis; 2011 Jan; 70(1):128-33. PubMed ID: 21062853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of progression from undifferentiated arthritis to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive patients.
    Feitsma AL; Toes RE; Begovich AB; Chokkalingam AP; de Vries RR; Huizinga TW; van der Helm-van Mil AH
    Rheumatology (Oxford); 2007 Jul; 46(7):1092-5. PubMed ID: 17341507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does a positive anti-CCP test identify a distinct arthritis entity?
    Skogh T
    Arthritis Res Ther; 2005; 7(6):230-2. PubMed ID: 16277697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palindromic rheumatism with positive anticitrullinated peptide/protein antibodies is not synonymous with rheumatoid arthritis. A longterm followup study.
    Sanmartí R; Cabrera-Villalba S; Gómez-Puerta JA; Ruiz-Esquide V; Hernández MV; Salvador G; Ramirez J; Viñas O; Cañete JD
    J Rheumatol; 2012 Oct; 39(10):1929-33. PubMed ID: 22859345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can we rely on anti-citrulline antibody determination for the diagnosis of early rheumatoid arthritis?
    Bell DA
    J Rheumatol; 2006 Dec; 33(12):2369-71. PubMed ID: 17143974
    [No Abstract]   [Full Text] [Related]  

  • 7. Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis.
    Goëb V; Dieudé P; Daveau R; Thomas-L'otellier M; Jouen F; Hau F; Boumier P; Tron F; Gilbert D; Fardellone P; Cornélis F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2008 Aug; 47(8):1208-12. PubMed ID: 18535030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased cartilage turnover and circulating autoantibodies in different subsets before the clinical onset of rheumatoid arthritis.
    Turesson C; Bergström U; Jacobsson LT; Truedsson L; Berglund G; Saxne T
    Ann Rheum Dis; 2011 Mar; 70(3):520-2. PubMed ID: 21081527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis.
    van der Woude D; Rantapää-Dahlqvist S; Ioan-Facsinay A; Onnekink C; Schwarte CM; Verpoort KN; Drijfhout JW; Huizinga TW; Toes RE; Pruijn GJ
    Ann Rheum Dis; 2010 Aug; 69(8):1554-61. PubMed ID: 20448290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Citrullinated peptide and its relevance to rheumatoid arthritis: an update.
    Luban S; Li ZG
    Int J Rheum Dis; 2010 Oct; 13(4):284-7. PubMed ID: 21199462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of high-throughput autoantibody profiling for the discovery of novel antigenic targets in rheumatoid arthritis.
    Somers K; Stinissen P; Somers V
    Ann N Y Acad Sci; 2009 Sep; 1173():92-102. PubMed ID: 19758137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Very early 'Rheumatoid' arthritis cohorts: limited by selection.
    Inanc M
    Rheumatology (Oxford); 2007 Feb; 46(2):185-7. PubMed ID: 17043049
    [No Abstract]   [Full Text] [Related]  

  • 14. Is it necessary to combine detection of anticitrullinated protein antibodies in the diagnosis of rheumatoid arthritis?
    Zhao J; Liu X; Wang Z; Liu R; Li Z
    J Rheumatol; 2010 Dec; 37(12):2462-5. PubMed ID: 20952480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
    J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional haplotypes of PADI4: relevance for rheumatoid arthritis specific synovial intracellular citrullinated proteins and anticitrullinated protein antibodies.
    Cantaert T; Coucke P; De Rycke L; Veys EM; De Keyser F; Baeten D
    Ann Rheum Dis; 2005 Sep; 64(9):1316-20. PubMed ID: 15760928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CCP antibodies as an aid to prioritization of patients referred to the rheumatology clinic.
    Madan A; Belshaw R; Grennan D
    QJM; 2007 Nov; 100(11):737-8. PubMed ID: 17951317
    [No Abstract]   [Full Text] [Related]  

  • 18. [Anti-cyclic citrullinated peptide (CCP) antibodies].
    Mimori T
    Nihon Rinsho; 2010 Jun; 68 Suppl 6():491-4. PubMed ID: 20942111
    [No Abstract]   [Full Text] [Related]  

  • 19. IgM-rheumatoid factor and anti-cyclic citrullinated peptide decrease by 50% during intensive treatment in early rheumatoid arthritis.
    van Tuyl LH; Lems WF; Kerstens PJ; Voskuyl AE; Dijkmans BA; Boers M
    Ann Rheum Dis; 2009 Oct; 68(10):1652-3. PubMed ID: 19748920
    [No Abstract]   [Full Text] [Related]  

  • 20. Duration of pre-rheumatoid arthritis anti-cyclic citrullinated peptide positivity is positively associated with age at seroconversion.
    Bos WH; Nielen MM; Dijkmans BA; van Schaardenburg D
    Ann Rheum Dis; 2008 Nov; 67(11):1642. PubMed ID: 18854513
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.